Indaptus Therapeutics, Inc.

NASDAQ:INDP

Biotechnology

Healthcare
$3.29 -2.21%

-$0.03 today

Market cap
$372.57M
Beta
1.14
P/E (TTM)
-0.2
EPS (TTM)
-$8.70
52W Low $0.92High $8.69

Volume 0.17M

Average 0.97M

INDP Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Indaptus Therapeutics, Inc.NASDAQ: INDP

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $2.54M (cash outflow) fell 43.9% year over year, behind the +19.7% change in trailing-twelve-month net income. Sequentially, it fell 68.7% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$6.13M (-70.6%) for the fiscal year ending Dec 2026, a slowdown from the +38.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.54M-68.7% QoQ
Last fiscal yearDec 2025
-$20.85M+38.8% YoY
LTMMar 2026
-$18.86M+19.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.9%-34.9%+9.0 pp
1 year+38.8%-70.6%-109.4 pp
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(20.85M) USD
Year-over-year change
-38.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How INDP compares with its peers on the latest reported figures

  • INDP's LTM Mar 2026 net income of $18.86M is the largest of the 2 companies compared; the peer median is $12.27M.
  • Its year-over-year change of +19.7% is the lowest of 2, against a peer median of +31.1%.
  • Over three fiscal years its annual growth of +13.3% compares with a peer median of +0.9%.
INDP Competitors Peer median
Net Income for INDP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$18.86M +19.7%+13.3%—
AZTRAzitra, Inc.LTM Jun 2026$12.27M +31.1%+0.9%—
Peer median (excluding INDP) $12.27M+31.1%+0.9%—

Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
Depreciation & Amortization1.4K1.78K1.28K7350
Deferred Income Tax(5.75M)0000
Stock-Based Compensation1.51M2.96M2.97M2.31M1.36M
Change in Working Capital(5.09M)(1.58M)(518.07K)392.26K3.51M
Accounts Receivables00000
Inventory00000
Accounts Payables(4.24M)(1.15M)(680.52K)474.06K2.85M
Other Working Capital(854.15K)(425.59K)162.45K(81.8K)665.3K
Other Non-Cash Items5.75M(134.16K)(430.99K)01.15M
Operating Cash Flow(11.29M)(13.08M)(13.41M)(12.32M)(14.82M)
Capital Expenditures(3.85K)(172.56K)00(4)
Acquisitions (Net)451.6K172.56K000
Purchases of Investments0(29.6M)(6.86M)00
Sales of Investments013M24M00
Other Investing Activities0172.56K000
Investing Cash Flow447.75K(16.43M)17.14M00
Debt Repayment00005.71M
Common Stock Issued5M005.51M11.83M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities43.34M00(762.7K)0
Financing Cash Flow48.34M004.75M17.54M
Effect of Forex Changes00000
Net Change in Cash37.49M(29.51M)3.74M(7.58M)2.72M
Free Cash Flow(11.29M)(13.25M)(13.41M)(12.32M)(14.82M)

Indaptus Therapeutics, Inc.

NASDAQ:INDP

Intrinsic Alpha fair value

Locked

Current Price

$3.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.